Abstract 3697
Background
Pancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.
Methods
Clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were followed up and evaluated. VCAN expression was assessed by immunohistochemical (IHC) methods, and the relationship between VCAN and prognostic features of pNET was analyzed.
Results
Among 161 pNET patients, 118 (73.3%) pNET were VCAN expression positive and 43 (26.7%) VCAN expression negative. Positive expression of VCAN in pNET was significantly associated with longer disease-free survival (DFS) compared with VCAN-negative pNET (p = 0.017, HR 0.399, 95%CI 0.215-0.741). Subgroup analysis showed that VCAN-positive expression was associated with longer DFS in the G1 subgroup (p = 0.030, HR = 0.122, 95%CI: 0.013-1.180), tumor size>2cm subgroup (p = 0.030, HR = 0.427, 95%CI: 0.193-0.944) and NF-pNET subgroup (p = 0.001, HR = 0.251, 95%CI: 0.103-0.617). Multiple analysis showed that VCAN-negative expression, G2 and tumor size>2cm were independent factors for poor prognosis in pNET (p = 0.01, p < 0.001, p = 0.009, respectively).
Conclusions
Our data indicate that VCAN-positive expression may serve as an independent factor for predicting DFS prognosis in pNET. VCAN-positive expression in pNET tissues was correlated with longer DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract